SecBot SecBot
8-K ·Filed Apr 3, 2026

TIL

Instil Bio, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC0001789769-26-000024
8-K material event: Items 4.01
Actionable Insight • Neutral

Monitor for future filings (10-Q, 10-K) to assess audit quality and financial reporting consistency under new auditor. The lack of full concurrence from Deloitte warrants caution despite clean audit history.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.46
T+0 close · Apr 3, 2026 · via day close
Latest settled
−9.10%
T+60 · $7.69
Vs SPY
−22.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $8.46entry
  2. T+1 · 7mo ago −0.12%α −0.18% · $8.45
  3. T+5 · 7mo ago −1.24%α −5.38% · $8.36
  4. T+20 · 7mo ago −7.33%α −16.31% · $7.84
  5. T+60 · 5mo ago −9.10%α −22.57% · $7.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Instil Bio, Inc. (TIL) dismissed Deloitte & Touche LLP as its independent auditor and appointed RSM US LLP effective April 1, 2026. Deloitte confirmed no disagreements or reportable events, but its letter indicates it cannot confirm the dismissal was not due to disagreements, raising caution.

Key Facts

  • Deloitte & Touche LLP was dismissed as auditor; RSM US LLP was appointed.
  • Deloitte's audit reports for 2024 and 2025 had no adverse opinions or qualifications.
  • No disagreements or reportable events were disclosed with Deloitte.
  • Deloitte's letter states it has no basis to agree or disagree with the dismissal reason, which may suggest undisclosed issues.
  • Company is an emerging growth company with no extended transition period election.

Financial Impact

No direct financial impact disclosed; change in auditor may signal internal shifts but no material weaknesses reported.

Risk Factors

  • Potential undisclosed disagreements with former auditor despite clean audit opinions.
  • Risk of future material weaknesses or restatements under new auditor RSM.
  • Market perception of auditor change as a red flag, especially for a small-cap biotech with limited financial disclosures.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001789769-26-000024
Document: seccessationofclient-audit.htm0001789769-26-000024
Document: 0001789769-26-000024-index-headers.html0001789769-26-000024
Document: 0001789769-26-000024-index.html0001789769-26-000024
Document: 0001789769-26-000024.txt0001789769-26-000024

Track record

8 reports on TIL

Performance horizon
Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry $6.22 Now $5.75 −7.56% settles Dec 15
  2. Aug 13, 202613w ago Press Release Neutral 4/10 No price data
  3. Aug 13, 202613w ago 8-K Neutral 4/10 Entry $7.38 to $7.45 Now $5.75 −22.09% ▲ +0.95% +2.94% vs SPY
  4. May 15, 202626w ago 8-K Neutral 4/10 No price data
  5. May 15, 202626w ago Press Release Neutral 4/10 Entry $8.07 to $7.92 Now $5.75 −28.75% ▼ −1.86% −3.98% vs SPY
  6. Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $8.13 to $8.12 Now $5.75 −29.27% ▼ −0.12% −5.08% vs SPY
  7. Apr 3, 202632w ago 8-K Neutral 4/10 Viewing Entry $8.46 to $7.84 Now $5.75 −32.03% ▼ −7.33% −16.31% vs SPY
  8. Mar 27, 202633w ago Press Release Mixed 5/10 Entry $7.79 to $8.13 Now $5.75 −26.19% ▲ +4.36% −8.38% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026